MetaVia to Present at Upcoming Investor and Industry Conferences
MetaVia (Nasdaq: MTVA), a clinical-stage biotech company specializing in cardiometabolic diseases, has announced its participation in several upcoming investor and industry conferences from September to October 2025.
CEO Hyung Heon Kim will attend the Wells Fargo Healthcare Conference (Sept 3-5), participate in a fireside chat at the H.C. Wainwright Global Investment Conference (Sept 8-10), present at the Obesity Science & Innovation Congress (Sept 16-17), and attend the Fierce Biotech Week (Oct 7-9). At the Obesity Science conference, Kim will showcase DA-1726, the company's dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity treatment.
MetaVia (Nasdaq: MTVA), azienda biotech in fase clinica specializzata nelle malattie cardiometaboliche, ha comunicato la sua partecipazione a diversi incontri con investitori e conferenze di settore previsti tra settembre e ottobre 2025.
Il CEO Hyung Heon Kim sar脿 presente al Wells Fargo Healthcare Conference (3-5 settembre), interverr脿 in un fireside chat al H.C. Wainwright Global Investment Conference (8-10 settembre), terr脿 una presentazione all'Obesity Science & Innovation Congress (16-17 settembre) e parteciper脿 al Fierce Biotech Week (7-9 ottobre). Durante l'evento Obesity Science, Kim presenter脿 DA-1726, l'analogo duale dell'oxyntomodulina dell'azienda che agisce su GLP1R e GCGR per il trattamento dell'obesit脿.
MetaVia (Nasdaq: MTVA), empresa biotecnol贸gica en fase cl铆nica especializada en enfermedades cardiometab贸licas, ha anunciado su asistencia a varias conferencias para inversores y del sector programadas entre septiembre y octubre de 2025.
El CEO Hyung Heon Kim asistir谩 al Wells Fargo Healthcare Conference (3-5 de septiembre), participar谩 en un fireside chat en el H.C. Wainwright Global Investment Conference (8-10 de septiembre), presentar谩 en el Obesity Science & Innovation Congress (16-17 de septiembre) y acudir谩 al Fierce Biotech Week (7-9 de octubre). En la conferencia sobre obesidad, Kim dar谩 a conocer DA-1726, el agonista an谩logo dual de oxyntomodulina de la compa帽铆a dirigido a GLP1R y GCGR para el tratamiento de la obesidad.
MetaVia (Nasdaq: MTVA)電� 鞁灔雽�靷� 歆堩櫂 攵勳暭鞚� 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 9鞗旊秬韯� 10鞗� 靷澊 臧滌禍霅橂姅 鞐煬 韴瀽鞛� 氚� 鞐呹硠 旖橅嵓霟办姢鞐� 彀戈皜頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟.
CEO 旯�順曧棇(Hyung Heon Kim)鞚� Wells Fargo Healthcare Conference(9鞗� 3鈥�5鞚�)鞐� 彀胳劃頃橁碃, H.C. Wainwright Global Investment Conference(9鞗� 8鈥�10鞚�)鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃橂┌, Obesity Science & Innovation Congress(9鞗� 16鈥�17鞚�)鞐愳劀 氚滍憸毳� 頃橁碃, Fierce Biotech Week(10鞗� 7鈥�9鞚�)鞐� 彀胳劃頃� 鞓堨爼鞛呺媹雼�. Obesity Science 旖橅嵓霟办姢鞐愳劀 旯� CEO電� 須岇偓鞚� 鞚挫 oxyntomodulin 鞙犾偓觳� 鞛戩毄鞝滌澑 DA-1726鞚� 靻岅皽頃� 鞓堨爼鞚措┌, 鞚措姅 GLP1R 氚� GCGR鞚� 響滌爜頃� 牍勲 旃橂毳� 氇╈爜鞙茧 頃╇媹雼�.
MetaVia (Nasdaq: MTVA), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les maladies cardiom茅taboliques, a annonc茅 sa participation 脿 plusieurs conf茅rences pour investisseurs et 茅v猫nements sectoriels pr茅vus entre septembre et octobre 2025.
Le CEO Hyung Heon Kim assistera au Wells Fargo Healthcare Conference (3-5 septembre), prendra part 脿 un fireside chat lors du H.C. Wainwright Global Investment Conference (8-10 septembre), pr茅sentera au Obesity Science & Innovation Congress (16-17 septembre) et participera au Fierce Biotech Week (7-9 octobre). Lors du congr猫s sur l'ob茅sit茅, Kim pr茅sentera DA-1726, l'agoniste analogue dual d'oxyntomoduline de la soci茅t茅 ciblant GLP1R et GCGR pour le traitement de l'ob茅sit茅.
MetaVia (Nasdaq: MTVA), ein klinisch gef眉hrtes Biotech-Unternehmen mit Schwerpunkt auf kardiometabolischen Erkrankungen, hat seine Teilnahme an mehreren Investoren- und Branchenkonferenzen von September bis Oktober 2025 angek眉ndigt.
CEO Hyung Heon Kim wird an der Wells Fargo Healthcare Conference (3.鈥�5. Sept.), in einem Fireside-Chat auf der H.C. Wainwright Global Investment Conference (8.鈥�10. Sept.) teilnehmen, beim Obesity Science & Innovation Congress (16.鈥�17. Sept.) pr盲sentieren und die Fierce Biotech Week (7.鈥�9. Okt.) besuchen. Auf der Obesity Science-Konferenz wird Kim DA-1726 vorstellen, den dualen Oxyntomodulin-Analogon-Agonisten des Unternehmens, der auf GLP1R und GCGR zur Behandlung von Adipositas abzielt.
- None.
- None.
- September 3-5: Wells Fargo Healthcare Conference. Hyung Heon Kim, President and Chief Executive Officer will attend this conference in
Boston, Massachusetts . - September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view beginning Friday, September 5, 2025, at 7:00 am ET on the H.C. Wainwright Conference Portal and on the Event Calendar page of the MetaVia website .
Institutional investors who are registered for the conference can log into to request a meeting with the company. - September 16-17: Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in
Boston, Massachusetts . - October 7-9: Fierce Biotech Week. Mr. Kim will attend this conference in
Boston, Massachusetts .
To schedule a meeting with management outside of these events, investors can contact Michael Miller at [email protected].
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit .
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]
Michael Miller
+1-917-633-6086
[email protected]听
View original content to download multimedia:
SOURCE MetaVia Inc.
FAQ
When is MetaVia (MTVA) presenting at the H.C. Wainwright Conference 2025?
What is MetaVia's (MTVA) drug candidate DA-1726?
Which conferences will MetaVia (MTVA) attend in September 2025?
How can investors schedule meetings with MetaVia (MTVA) management?
